Ethypharm India, the 100% subsidiary of leading global NDDS company Ethypharm S.A. of France, signed an out-licensing and supply contract for Cetirizine 10 mg Orodispersible tablets with Globalpharma for the GCC markets.

Under the terms of the agreement, Ethypharm will be responsible for the development of an orally disintegrating formulation of Cetirizine tablet, using its proprietary T-Mask technology. This new formulation combines several benefits in terms of acceptability, accuracy of dosing and safety. With Ethypharm's T-Mask technology, drugs are made easier to swallow and more pleasant to taste, according to a release.

The product will be supplied from Ethypharm's manufacturing facility near Mumbai as a penultimate stage bulk formulation and will then be converted to a finished formulation at Globalpharma under technical supervision from Ethypharm. In turn, Globalpharma is responsible for marketing and distribution in Gulf Cooperation Council markets, under their brand name.
Cetrizine is mainly indicated for Allergic Rhinitis, Urticaria and symptoms of hypersensitivity reactions.

Globalpharma Co. LLC is a leading joint venture company in the UAE with majority shareholding from Dubai Investment PJC. "Globalpharma is discussing more deals with Ethypharm to cement Globalpharma's position as the premier Pharma Company of the GCC area," says Maged Amer, General Manager of Globalpharma.